Activated protein C resistance: The influence of ABO-blood group, gender and age

Thrombosis Research

Volumn 117, Issue 6, 2006, Pages 665-670

  Favaloro, Emmanuel J ^a   Soltani, Soma ^a   McDonald, Jane ^a   Grezchnik, Ella ^a   Easton, Leanne ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

ABO blood group; Activated Protein C Resistance; Age; Familial thrombophilia; Gender; Laboratory assessment; Normal reference ranges

Indexed keywords

ACTIVATED PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; EVALUATION; FAMILIAL DISEASE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RUSSEL VIPER VENOM TIME; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; THROMBOPHILIA;

ABO BLOOD-GROUP SYSTEM; ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AUSTRALIA; BLOOD COAGULATION TESTS; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE STANDARDS; SEX FACTORS; THROMBOPHILIA;

EID: 33646018596     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.06.011     Document Type: Article

References (43)

1. Mannucci P.M. Laboratory detection of inherited thrombophilia: an historical perspective. Semin Throm Haemost 31 (2005) 5-10
2. Walker I.D., Greaves M., Preston F.E., on behalf of the Haemostasis and Thrombosis Task Force, and British Committee for Standards in Haematology. Guideline: investigation and management of heritable thrombophilia. Br J Haematol 114 (2001) 512-528
3. Tripodi A. A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia. Semin Throm Haemost (2005) 25-32
4. Favaloro E.J. Diagnostic issues in thrombophilia: a laboratory scientist's view. Semin Throm Haemost 31 (2005) 11-16
5. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 1 (2003) 410-411
6. Machin S.J. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 1 (2003) 412-413
7. Martinelli I. Rebuttal to: pros and cons of thrombophilia testing: pros. J Thromb Haemost 1 (2003) 1311-1312
8. Van Cott E.M., Laposata M., and Prins M.H. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis: venous thromboembolism, myocardial infarction, stroke, and other conditions. Arch Pathol Lab Med 126 (2002) 1281-1295
9. De Stefan V., Ross E., Paciaron K., and Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 87 (2002) 1095-1108
10. Favaloro E.J., Mirochnik O., and McDonald D. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT- than APTT-based assays. Br J Biomed Sci 56 (1999) 23-33
11. Favaloro E.J., Orsag I., Bukuya M., and McDonald D. A nine-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. Pathology 34 (2002) 348-355
12. Favaloro E.J., Bonar B., Sioufi J., Wheeler M., Low J., Aboud M., et al., on behalf of the RCPA QAP in Haematology. Multi-laboratory testing of thrombophilia: current and past practice in Australasia as assessed through the RCPA Haematology QAP. Semin Throm Haemost 31 (2005) 49-58
13. Hertzberg M., Neville S., Favaloro E.J., and MacDonald D. External quality assurance of DNA testing for thrombophilia mutations. Am J Clin Pathol 123 (2005) 189-193
14. Favaloro E.J. Learning from the peer-assessment external quality assurance multi-laboratory thrombophilia test process. Semin Throm Haemost 31 (2005) 85-89
15. Mirochnik O., Halim-Kertanegar N., Henniker A.J., Favaloro E.J., Tiley C.R., Hertzberg M., et al. A null Factor V Null mutation at Arg 506 causes a false positive Factor V Leiden result. Thromb Haemost 82 (1999) 1198-1199
16. Bronte-Stewart B., Botha M.C., and Krut L.H. ABO blood groups in relation to ischaemic heart disease. BMJ 1 (1962) 1646-1650
17. Jick H., Slone D., Westerholm B., Inman W.H., Versey M.P., Shapiro S., et al. Venousthromboembolic disease and ABO blood type. Lancet 1 (1969) 539-542
18. O'Donnell J.O., and Laffan M.A. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 11 (2001) 343-351
19. Shima M., Fujimura Y., Nishiyama T., Tsujiuchi T., Narita N., Matsui T., et al. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 68 (1995) 236-240
20. Nitu-Whalley I.C., Lee C.A., Griffioen A., Jenkins P.V., and Pasi K.J. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 108 (2000) 259-264
21. Schleef M., Strobel E., Dick A., Frank J., Schramm W., and Spannagl M. Relationship between ABO and secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 128 (2004) 100-107
22. Ray K.K., Francis S., and Crossman D.C. Measurement of plasma von Willebrand factor in acute coronary syndromes and the influence of the ABO blood group status. J Thromb Haemost 2 (2004) 2053-2054
23. Matyskova M., Zavrelova J., Pejchalova A., Meluzinova H., and Janku L. ABO/H blood groups and factor V Leiden. Cas Lek Ces 141 (2002) 146-151
24. Morelli V.M., De Visser M.C., Vos H.L., Bertina R.M., and Rosendaal F.R. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. Thromb Haemost 3 1 (2005, Jan) 183-185
25. Clark P., Sattar N., Walker I.D., and Greer I.A. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance. Thromb Haemost 85 (2001) 30-35
26. Sampram E.S., Lindblad B., and Dahlback B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 28 (1998) 624-629
27. de Visser M.C., Rosendaal F.R., and Bertina R.M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93 (1999) 1271-1276
28. Rodeghiero F., and Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 130 (1999) 643-650
29. Svensson P.J., Benoni G., Fredin H., Bjorgell O., Nilsson P., Hedlund U., et al. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost 78 (1997) 993-996
30. Bennet L., and Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 244 (1998) 27-32
31. Thorogood M. Oral contraceptives and thrombosis. Curr Opin Hematol 5 (1998) 350-354
32. Gerhardt A., Scharf R.E., and Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 90 1 (2003 (Jul)) 77-85
33. Faioni E.M., Razzari C., Martinelli I., Panzeri D., Franchi F., and Mannucci PM. Resistance to activated protein C in unselected patients with arterial and venous thrombosis. Am J Hematol. 55 2 (1997 (Jun)) 59-64
34. Larsen T.B., Johnsen S.P., Gislum M., Moller C.A., Larsen H., and Sorensen H.T. ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. J Thromb Haemost 3 2 (2005 (Feb)) 300-304
35. De Mitrio V., Marino R., Cicinelli E., Galantino P., Di Bari L., Giannoccaro F., et al. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C. Blood Coagul Fibrinolysis 11 (2000) 175-182
36. Hoffman R., and Brenner B. Thrombophilia related issues in women and children. Semin Throm Haemost 31 (2005) 97-103
37. Fassett M.J., Bohn Y.C., Kuo J., and Wing D.A. Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women. Am J Obstet Gynecol 182 (2000) 1433-1436
38. Allman-Farinelli M., and Dawson B. Diet and aging: bearing on thrombosis and haemostasis. Semin Throm Haemost 31 (2005) 111-117
39. Oger E., Lacut K., Le Gal G., Van Dreden P., Bressollette L., Scarabin P.Y., et al. Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?. Thromb Haemost 88 (2002) 587-591
40. Kuhli C., Hattenbach L.O., Scharrer I., Koch F., and Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefe Arch Clin Exp Ophthalmol 240 (2002) 163-168
41. Zunker P., Hohenstein C., Plendl H.J., Zeller J.A., Caso V., Georgiadis D., et al. Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age. J Neurol 248 (2001) 701-704
42. Jerrard-Dunne P., Evans A., McGovern R., Hajat C., Kalra L., Rudd A.G., et al. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study. Stroke 34 (2003) 1821-1826
43. Miller C.H., Haff E., Platt S.J., Rawlings P., Drews C.D., Dilley A.B., et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 1 (2003) 2191-2197